Clincosm LogoSign in Get a demo

Prognostic Factors of Patients With COVID-19

Sponsor
Chongqing Medical University (Other)
Overall Status
Completed
CT.gov ID
NCT04292964
Collaborator
(none)
201
Enrollment
1
Location
12
Actual Duration (Days)
509.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. Despite lower mortality rate, SARS-CoV-2 has killed more people than SARS and MERS and the number keeps growing. Epidemic studies have been well described clinical features of patients with COVID-19, with the disease severity being an independent predictor of poor outcome. However, there is still no research investigating the prognostic factors of patients with COVID-19.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    201 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Prognostic Factors of Patients With COVID-19
    Actual Study Start Date :
    Mar 1, 2020
    Actual Primary Completion Date :
    Mar 13, 2020
    Actual Study Completion Date :
    Mar 13, 2020

    Outcome Measures

    Primary Outcome Measures

    1. all-cause mortality [30 days]

    Secondary Outcome Measures

    1. all-cause mortality [15 days]

    2. Severe state [15 days]

      Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Adult aged >=18years old;

    • Diagnosed with CONVID19. Diagnostic criteria including: Laboratory (RT-PCR) confirmed SARS-Cov-2 infection; CT of the lung conformed to the manifestation of viral pneumonia.

    • Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg.

    Exclusion Criteria:

    • Near-death state (expected survival time less than 24 hours);

    • Malignant tumor;

    • Pregnancy or puerperium women;

    • Patients who refused to participant.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The First Affiliated Hospital of Chongqing Medical University Chongqing China

    Sponsors and Collaborators

    • Chongqing Medical University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dongying Zhang, Clinical Professor, Chongqing Medical University
    ClinicalTrials.gov Identifier:
    NCT04292964
    Other Study ID Numbers:
    • 2020-02-2
    First Posted:
    Mar 3, 2020
    Last Update Posted:
    Mar 17, 2020
    Last Verified:
    Mar 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Mar 17, 2020